The world's first!
It is independently developed by Centstar Biotech
Liver Cancer Auxiliary Diagnostic Kit "Jietaiji"
Officially approved for marketing
This is the first one approved for marketing in China Medical City
National innovative medical device products
Recently, the liver cancer auxiliary diagnosis product (trade name: Jietaisi) independently developed by Xianstar Biotech has officially obtained the Class III medical device registration certificate from the National Medical Products Administration (NMPA), becoming the world's first tumor auxiliary diagnosis IVD product developed based on glycome technology, and the first national innovative medical device product approved for marketing in China Medical City. Gentex can greatly improve the detection rate of patients with early-stage liver cancer, effectively fill the clinical gap, and bring revolutionary changes to the auxiliary diagnosis of related tumors.
According to the official website of the National Medical Products Administration, the "oligosaccharide chain detection kit (fluorescent capillary electrophoresis)" of Centstar Biotech is independently developed in mainland China, which uses capillary electrophoresis to qualitatively detect 9 oligosaccharide chains in human serum samples, which is used for the auxiliary diagnosis of primary hepatocellular carcinoma in patients with hepatitis B cirrhosis. The product assists in diagnosis through non-invasive detection methods, which is helpful for the prevention and treatment of primary hepatocellular carcinoma.
About Jeteji
Centstar Biotech has carried out long-term exploration and practice in the field of glycomics, and has successfully developed "Jietaisi", a breakthrough auxiliary diagnostic product for liver cancer. By detecting the sugar chain in human serum, Jietaisi assesses the risk of liver cancer through big data and artificial intelligence analysis, helping clinicians diagnose liver cancer earlier.
Clinical data show that the sensitivity and specificity of Jietaisi ® in detecting liver cancer are 88.54% and 95.21%, both of which have reached the international leading level. Among them, the detection sensitivity of Jietaisi ® is as high as 87.76% for early liver cancer, 84.03% for cases with negative AFP (alpha-fetoprotein) detection, ® and 87.50% for patients with liver cancer with atypical imaging, showing extremely superior clinical performance.
▲NEWS
【Small Links】
Founded in 2014 by Dr. Chen Cuiying, a returned expert from Belgium, Jiangsu Xiansida Biotechnology Co., Ltd. is a biomedical enterprise integrating the R&D, production and sales of collective external diagnostic reagents and instruments with applied glycomics as the core. Focusing on the two major fields of tumor diagnosis and physiological health, Centstar Biotech empowers the industry from a new glycomics dimension based on the glycome detection and analysis technology platform established by independent research and development.
Source: Taizhou Xingao release